Parallel Advisors’s Regulus Therapeutics RGLS Stock Holding History

Parallel Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10	Closed	-$18	–	3460
2024 Q2	$18	Buy	+10	New	+$23	﹤0.01%	3289

Other funds holding RGLS

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Parallel Advisors's RGLS Position: Q3 2024 in Review

Parallel Advisors sold out of Regulus Therapeutics (RGLS) in Q3 2024, closing a stake of 10 shares — an estimated $18 sold.

Parallel Advisors first reported a position in RGLS in Q2 2024 and held it in 1 quarter. The position peaked at $18 in Q2 2024. 70 funds tracked by Wall St. Rank hold RGLS as of Q3 2024.

Parallel Advisors reported no remaining Regulus Therapeutics position as of Q3 2024 after selling out during the quarter.
Parallel Advisors sold 10 Regulus Therapeutics shares in Q3 2024, an estimated $18.
Parallel Advisors first reported a position in Regulus Therapeutics in Q2 2024 and held it in 1 quarter.
Parallel Advisors's Regulus Therapeutics position peaked at $18 in Q2 2024.
70 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.